AstraZeneca lung and breast cancer data at WCLC and ESMO.
The Pharma Data
SEPTEMBER 2, 2021
Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settings. DESTINY-Breast03 is the first global Phase III trial of Enhertu against an active control.
Let's personalize your content